Carfilzomib for Injection 30mg
CARFLIEVA 30MG (Carfilzomib for Injection 30mg) is a specialized anticancer medicine used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It contains Carfilzomib, a highly effective proteasome inhibitor that helps slow down and control the growth of cancer cells in the body. This oncology injection is commonly prescribed by healthcare professionals as part of advanced chemotherapy and targeted cancer treatment protocols.
Multiple myeloma develops when abnormal plasma cells multiply uncontrollably inside the bone marrow. These cancerous cells interfere with the normal production of blood cells and can weaken bones, reduce immunity, and affect kidney function. CARFLIEVA 30MG works by targeting and blocking proteasomes, which are responsible for breaking down proteins inside cancer cells. When proteasomes are inhibited, cancer cells accumulate damaged proteins and eventually die, helping reduce the spread of the disease.
CARFLIEVA 30MG is widely used in modern oncology treatment because of its effectiveness in managing relapsed or refractory multiple myeloma. It is often prescribed for patients who have previously received other cancer therapies but require further treatment support due to disease progression or recurrence. Doctors may use this medicine alone or in combination with other anticancer medicines depending on the patient’s condition and treatment plan.
This Carfilzomib injection is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable clinical performance. The medicine is intended for hospital and oncology center use and should only be administered by trained healthcare professionals under proper medical supervision.
Patients receiving CARFLIEVA 30MG usually undergo regular medical monitoring, blood tests, and health assessments during treatment to help improve treatment outcomes and reduce the risk of complications. Oncology specialists carefully determine the dosage and treatment schedule based on the patient’s overall health, response to therapy, and stage of cancer.
Due to its advanced mechanism of action and targeted cancer therapy approach, CARFLIEVA 30MG has become an important medicine in the management of multiple myeloma and modern hematology-oncology treatment protocols.
View Details
Ibrutinib Capsules 140mg
IBRULIEVA contains Ibrutinib, a first-generation Bruton’s Tyrosine Kinase (BTK) inhibitor. It blocks BTK signaling in B-cells, thereby inhibiting the growth and survival of malignant B-lymphocytes.
View Details
Melphalan Tablet IP 2mg
MELIEVA contains Melphalan, an alkylating anticancer agent. It works by cross-linking DNA strands, thereby inhibiting DNA and RNA synthesis and leading to the death of rapidly dividing cancer cells.
View Details
Acalabrutinib Capsules 100mg
ACALIEVA contains Acalabrutinib, a second-generation Bruton’s Tyrosine Kinase (BTK) inhibitor. It works by blocking BTK signaling in B-cells, thereby inhibiting the growth and survival of malignant B-lymphocytes.
View Details
Hydroxyurea Capsules IP 500mg
HYDLIEVA contains Hydroxyurea, an oral antineoplastic agent. It works by inhibiting ribonucleotide reductase, which interferes with DNA synthesis, slowing or stopping the growth of rapidly dividing cancer cells.
View Details
Imatinib Mesylate Tablets IP 400mg
IMALIEVA contains Imatinib Mesylate, a targeted anticancer medicine. It works as a tyrosine kinase inhibitor (TKI) by blocking enzymes (BCR-ABL, c-KIT, PDGFR) that signal cancer cell growth, thereby slowing or stopping cancer progression.
View Details
Azacitidine for Injection 100MG
AZALIEVA 100 mg contains Azacitidine, a hypomethylating agent and pyrimidine nucleoside analogue. It incorporates into DNA and RNA, leading to inhibition of DNA methyltransferase, reactivation of tumor suppressor genes, and normalization of bone marrow function. It is mainly used in myelodysplastic syndromes (MDS).
View Details
Plerixafor Injection 24mg
MOZOLIEVA 24 mg contains Plerixafor, a hematopoietic stem cell mobilizer. It is a CXCR4 chemokine receptor antagonist that disrupts the interaction between CXCR4 and SDF-1α, causing rapid release of CD34+ stem cells from the bone marrow into peripheral blood for collection.
View Details
Fludarabine Phosphate for Injection 50mg
FLULIEVA 50 mg contains Fludarabine Phosphate, a purine nucleoside analogue antimetabolite. It is intracellularly converted to fludarabine triphosphate, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to suppression of DNA synthesis and apoptosis. It is widely used in hematologic malignancies.
View Details
Methotrexate Injection 500mg
TREXLIEVA 500 mg contains Methotrexate, an antimetabolite and antifolate chemotherapeutic agent. It inhibits dihydrofolate reductase (DHFR), blocking folate metabolism and DNA synthesis in rapidly dividing cells. This strength is commonly used in high-dose methotrexate (HD-MTX) oncology protocols.
View Details
Methotrexate Injection IP 50mg
TREXLIEVA 50 mg contains Methotrexate, an antimetabolite and antifolate chemotherapeutic agent. It inhibits dihydrofolate reductase (DHFR), leading to reduced DNA synthesis and cell replication, particularly in rapidly dividing cells. It is widely used in oncology, autoimmune diseases, and medical oncology protocols.
View Details
Bortezomib Injection IP 3.5mg
BORTLIEVA contains Bortezomib, a proteasome inhibitor used in cancer treatment. It works by blocking proteasomes in cells, leading to accumulation of proteins and apoptosis (cell death) of cancer cells.
View Details
